Kymera Therapeutics (KYMR) Short-term Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Short-term Investments for 8 consecutive years, with $506.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 35.81% year-over-year to $506.8 million; the TTM figure through Mar 2026 stood at $506.8 million (up 35.81% YoY), while the FY2025 annual figure was $491.3 million, up 33.32% from the prior year.
• Short-term Investments climbed to $506.8 million in Q1 2026 per KYMR's latest filing, from $491.3 million in the prior quarter.
• Across five years, Short-term Investments topped out at $506.8 million in Q1 2026 and bottomed at $264.9 million in Q4 2023.
• Historically, Short-term Investments has averaged $376.0 million across 5 years, with a median of $368.5 million in 2024.
• Annual changes were most pronounced in 2024 — Short-term Investments soared 58.7% — and 2025, when it declined 25.48%.
• Kymera Therapeutics' Short-term Investments stood at $338.8 million in 2022, then decreased by 21.8% to $264.9 million in 2023, then surged by 39.1% to $368.5 million in 2024, then soared by 33.32% to $491.3 million in 2025, then rose by 3.17% to $506.8 million in 2026.
• Business Quant data shows KYMR's Short-term Investments at $506.8 million in Q1 2026, $491.3 million in Q4 2025, and $392.7 million in Q3 2025.